Beta Bionics' Mark Hopman sells 370 shares

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 370 shares of common stock on October 1, 2026, at a weighted average sale price of $18.96 per share under a Rule 10b5-1 plan adopted on June 10, 2026.

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 370 shares of common stock on October 1, 2026, at a weighted average sale price of $18.96 per share under a Rule 10b5-1 plan adopted on June 10, 2026. Prices ranged from $18.96 to $19.9599 per share. After the sale, he held 56,109 shares directly.

Insider Trade Summary

Net Seller: 370 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 370 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	370	$18.96	$7K

Holdings After Transaction: Common Stock — 56,109 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
2. F2. The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 370 shares Weighted average sale price: $18.96 per share Sale price range: $18.96–$19.9599 per share +1 more

4 metrics

Shares sold 370 shares October 1, 2026

Weighted average sale price $18.96 per share October 1, 2026 sale

Sale price range $18.96–$19.9599 per share October 1, 2026 sale

Direct shares held after sale 56,109 shares Following the October 1, 2026 sale

Key Terms

Rule 10b5-1 Plan, weighted average sale price

2 terms

Rule 10b5-1 Plan regulatory

"pursuant to a Rule 10b5-1 Plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did BBNX Chief Commercial Officer Mark Hopman sell?

Mark Hopman sold 370 shares of BBNX common stock on October 1, 2026, at a weighted average price of $18.96 per share. The sale was made under a Rule 10b5-1 plan adopted June 10, 2026.

What was the price range for Mark Hopman's BBNX share sale?

Prices ranged from $18.96 to $19.9599 per share. Upon request by SEC staff, Beta Bionics, Inc., or any security holder, full information about the number of shares sold at each separate price will be provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 05:11 PM Accepted by SEC EDGAR 10/05/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		S(1)		370	D	$18.96(2)	56,109	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

2. The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Remarks:

	/s/ Stephen Feider, Attorney-in-Fact	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)